- Home
- EIC vs VNDA Comparison
EIC vs VNDA Comparison
Compare EIC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- VNDA
- Stock Information
- Founded
- EIC N/A
- VNDA 2002
- Country
- EIC United States
- VNDA United States
- Employees
- EIC N/A
- VNDA N/A
- Industry
- EIC Finance/Investors Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- VNDA Health Care
- Exchange
- EIC Nasdaq
- VNDA Nasdaq
- Market Cap
- EIC 349.4M
- VNDA 288.2M
- IPO Year
- EIC 2019
- VNDA 2006
- Fundamental
- Price
- EIC $13.53
- VNDA $4.76
- Analyst Decision
- EIC Strong Buy
- VNDA Strong Buy
- Analyst Count
- EIC 1
- VNDA 3
- Target Price
- EIC $17.50
- VNDA $15.33
- AVG Volume (30 Days)
- EIC 195.3K
- VNDA 455.3K
- Earning Date
- EIC 08-05-2025
- VNDA 07-30-2025
- Dividend Yield
- EIC 17.73%
- VNDA N/A
- EPS Growth
- EIC N/A
- VNDA N/A
- EPS
- EIC 0.55
- VNDA N/A
- Revenue
- EIC $51,224,692.00
- VNDA $201,351,000.00
- Revenue This Year
- EIC $42.67
- VNDA $16.86
- Revenue Next Year
- EIC $29.16
- VNDA $39.78
- P/E Ratio
- EIC $24.54
- VNDA N/A
- Revenue Growth
- EIC 68.61
- VNDA 13.37
- 52 Week Low
- EIC $12.63
- VNDA $3.81
- 52 Week High
- EIC $16.71
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- EIC 46.59
- VNDA 51.75
- Support Level
- EIC $13.38
- VNDA $4.67
- Resistance Level
- EIC $14.05
- VNDA $5.04
- Average True Range (ATR)
- EIC 0.21
- VNDA 0.21
- MACD
- EIC 0.01
- VNDA -0.01
- Stochastic Oscillator
- EIC 26.71
- VNDA 51.35
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.